Beyond SARS-CoV-2: epidemiological surveillance of respiratory viruses in Jalisco, Mexico.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Frontiers Editorial Office Country of Publication: Switzerland NLM ID: 101616579 Publication Model: eCollection Cited Medium: Internet ISSN: 2296-2565 (Electronic) Linking ISSN: 22962565 NLM ISO Abbreviation: Front Public Health Subsets: MEDLINE
    • Publication Information:
      Original Publication: Lausanne : Frontiers Editorial Office
    • Subject Terms:
      Influenza, Human*/epidemiology ; Respiratory Tract Infections*/epidemiology ; COVID-19*/epidemiology ; Viruses*; Humans ; SARS-CoV-2 ; Mexico/epidemiology ; Phylogeny
    • Abstract:
      Introduction: Respiratory viral infections represent a significant global health burden. Historically, influenza, rhinovirus, respiratory syncytial virus, and adenovirus have been the prevalent viruses; however, the landscape shifted with the widespread emergence of SARS-CoV-2. The aim of this study is to present a comprehensive epidemiological analysis of viral respiratory infections in Jalisco, Mexico.
      Methods: Data encompassing individuals with flu-like symptoms from July 2021 to February 2023 was scrutinized for viral diagnosis through PCR multiplex. The effect of social mobility on the increase in respiratory viral diagnosis infection was considered to estimate its impact. Additionally, sequences of respiratory viruses stored in public databases were retrieved to ascertain the phylogenetic classification of previously reported viruses in Mexico.
      Results: SARS-CoV-2 was the most detected virus ( n  = 5,703; 92.2%), followed by influenza ( n  = 479; 7.78%). These viruses were also found as the most common co-infection ( n  = 11; 50%), and for those with influenza, a higher incidence of severe disease was reported ( n  = 122; 90.4%; p  < 0.001). Regarding comorbidities and unhealthy habits, smoking was found to be a risk factor for influenza infection but a protective factor for SARS-CoV-2 (OR = 2.62; IC 95%: 1.66-4.13; OR = 0.65; IC 95%: 0.45-0.94), respectively. Furthermore, our findings revealed a direct correlation between mobility and the prevalence of influenza infection (0.214; p  < 0.001).
      Discussion: The study presents evidence of respiratory virus reemergence and prevalence during the social reactivation, facilitating future preventive measures.
      Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
      (Copyright © 2024 Pedroza-Uribe, Vega Magaña, Muñoz-Valle, Peña-Rodriguez, Carranza-Aranda, Sánchez-Sánchez, Venancio-Landeros, García-González, Zavala-Mejía, Ramos-Solano, Viera-Segura and García-Chagollán.)
    • References:
      Int J Environ Res Public Health. 2021 Oct 11;18(20):. (PMID: 34682388)
      Respirology. 2016 May;21(4):648-55. (PMID: 26919484)
      Pediatr Infect Dis J. 2013 May;32(5):441-5. (PMID: 23838658)
      Nat Rev Microbiol. 2023 Mar;21(3):195-210. (PMID: 36253478)
      Infect Dis Poverty. 2023 Mar 9;12(1):15. (PMID: 36895021)
      Virol J. 2023 Apr 11;20(1):65. (PMID: 37041586)
      Lancet Infect Dis. 2018 Nov;18(11):1191-1210. (PMID: 30243584)
      Int J Infect Dis. 2020 Sep;98:21-32. (PMID: 32562851)
      JMIR Public Health Surveill. 2021 Aug 30;7(8):e29957. (PMID: 34174780)
      Lancet Infect Dis. 2017 Oct;17(10):e320-e326. (PMID: 28457597)
      Rev Med Virol. 2021 May;31(3):e2179. (PMID: 33035373)
      Front Public Health. 2023 Apr 27;11:1149795. (PMID: 37181688)
      Child Youth Serv Rev. 2020 Sep;116:105160. (PMID: 32834269)
      Adv Clin Exp Med. 2021 Jan;30(1):109-114. (PMID: 33529514)
      Arch Bronconeumol. 2015 Jan;51(1):5-9. (PMID: 24666712)
      Viruses. 2023 May 13;15(5):. (PMID: 37243246)
      Pathogens. 2021 Dec 17;10(12):. (PMID: 34959590)
      BMJ Evid Based Med. 2021 Dec;26(6):279-284. (PMID: 32788164)
      J Glob Health. 2020 Jun;10(1):010426. (PMID: 32566164)
      Medicine (Baltimore). 2015 Dec;94(50):e2332. (PMID: 26683973)
      Lancet. 2022 May 28;399(10340):2047-2064. (PMID: 35598608)
      Emerg Infect Dis. 2022 Feb;28(2):273-281. (PMID: 35075991)
      Pneumologie. 2017 Apr;71(4):221-226. (PMID: 27912214)
      Int J Environ Res Public Health. 2022 Dec 30;20(1):. (PMID: 36612967)
      Int J Mol Sci. 2020 Sep 09;21(18):. (PMID: 32916821)
      J Formos Med Assoc. 2021 Dec;120(12):2195-2196. (PMID: 34503903)
      PLoS One. 2017 May 3;12(5):e0176298. (PMID: 28467515)
      Front Cell Infect Microbiol. 2023 Apr 04;13:1142199. (PMID: 37153160)
      J Infect. 2019 Nov;79(5):401-406. (PMID: 31465780)
      PLoS One. 2014 Jun 16;9(6):e99392. (PMID: 24932493)
      J Infect Public Health. 2021 Sep;14(9):1186-1190. (PMID: 34399190)
      Clin Microbiol Infect. 2015 Mar;21(3):264.e1-6. (PMID: 25596778)
      Emerg Infect Dis. 2007 Sep;13(9):1307-13. (PMID: 18252100)
      Tob Use Insights. 2022 Aug 8;15:1179173X221114799. (PMID: 35966408)
      J Med Virol. 2008 Apr;80(4):716-23. (PMID: 18297694)
      Nicotine Tob Res. 2023 Jan 5;25(2):211-220. (PMID: 35368066)
      Salud Publica Mex. 2010 Nov-Dec;52(6):528-32. (PMID: 21271012)
      Nat Commun. 2021 Feb 12;12(1):1001. (PMID: 33579926)
    • Contributed Indexing:
      Keywords: SARS-CoV-2; clinical impact; epidemiological survey; respiratory viruses; viral coinfections
    • Publication Date:
      Date Created: 20240126 Date Completed: 20240129 Latest Revision: 20240501
    • Publication Date:
      20240501
    • Accession Number:
      PMC10808461
    • Accession Number:
      10.3389/fpubh.2023.1292614
    • Accession Number:
      38274524